SEC Company Response from PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744) (PPBT) — Dec 12, 2016
PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744)
Date: Dec. 12, 2016 · CIK: 0001614744 · Accession: 0001213900-16-019311
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-215037
Letter
Kitov Pharmaceuticals Holdings Ltd.
One Azrieli Center, Round Tower, 23rd Floor
32 Menachem Begin Road
Tel Aviv 6701101, Israel
+972-3-933-3121
December 12, 2016
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Josh Samples and Suzanne Hayes
Re: Kitov Pharmaceuticals Holdings Ltd.
Registration Statement on Form F-3
Filed December 12, 2016
File No. 333-215037 (the “Registration Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Kitov Pharmaceuticals Holdings Ltd. (the “Company”) hereby respectfully requests acceleration of the effective date of the Registration Statement so that it may become effective at 5:00 p.m., Eastern Time, on December 14, 2016, or as soon thereafter as practicable.
In connection with the Company’s request for acceleration of the effective date of the Registration Statement, the Company acknowledges the following:
· should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
Kitov Pharmaceuticals Holdings Ltd.
Show Raw Text
CORRESP
1
filename1.htm
Kitov Pharmaceuticals Holdings Ltd.
One Azrieli Center, Round Tower, 23rd Floor
32 Menachem Begin Road
Tel Aviv 6701101, Israel
+972-3-933-3121
December 12, 2016
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Josh Samples and Suzanne Hayes
Re: Kitov Pharmaceuticals Holdings Ltd.
Registration Statement on Form F-3
Filed December 12, 2016
File No. 333-215037 (the “Registration
Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated
under the Securities Act of 1933, as amended, Kitov Pharmaceuticals Holdings Ltd. (the “Company”) hereby
respectfully requests acceleration of the effective date of the Registration Statement so that it may become effective at 5:00
p.m., Eastern Time, on December 14, 2016, or as soon thereafter as practicable.
In connection with the
Company’s request for acceleration of the effective date of the Registration Statement, the Company acknowledges the following:
· should the Securities and Exchange Commission (the “Commission”) or the
staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any
action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring
the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in
any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should any member of the
staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone,
LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
Kitov Pharmaceuticals Holdings Ltd.
By:
/s/ Isaac Israel
Name: Isaac Israel
Title: Chief Executive Officer